Ann: Appendix 4C and Quarterly Update, page-32

All of that is worth nought NZT...if the company can't develop and sell it. Which is exactly what has happened.

Now most of the focus appears to be on MND, rather than the stuff that's been in the pipeline for many years. They can rabbit on all they like about all these other things, the fact that they now appear to be focusing most of their efforts on MND speaks volumes to me about where the previous applications sit and what they value it at. What was once at the forefront of their thinking...is now an afterthought. If MND results aren't spectacular, PAA is toast.

Still watching with interest however. Continued GLTAH.